What's Happening?
Researchers at the University of Pennsylvania have developed a bioengineered chewing gum that could reduce the risk of mouth and throat cancer, particularly squamous cell carcinoma, which is linked to HPV and certain bacteria. The gum, made from lablab
beans, contains an antiviral protein that significantly reduces HPV and harmful bacteria levels in the mouth. The addition of protegrin, an antimicrobial peptide, further enhances its effectiveness without affecting beneficial oral bacteria. This innovation could serve as an adjunct therapy or preventive measure alongside existing treatments.
Why It's Important?
This development represents a potential breakthrough in cancer prevention and treatment, particularly for high-risk individuals. By targeting the microbes associated with mouth and throat cancer, the gum could reduce the incidence of these cancers, which are often linked to HPV infections. The ability to preserve beneficial bacteria while eliminating harmful ones could improve patient outcomes and reduce the side effects associated with traditional treatments like radiation therapy. This approach aligns with broader efforts to develop non-invasive, preventive healthcare solutions that can be easily integrated into daily routines.
